ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF

[1]  Kari Stefansson,et al.  Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. , 2017, Blood.

[2]  M. Cazzola,et al.  Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. , 2017, Blood.

[3]  M. Cazzola,et al.  Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. , 2017, Blood.

[4]  W. Vainchenker,et al.  Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. , 2017, Blood.

[5]  L. Bullinger,et al.  Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis , 2017, Leukemia.

[6]  C. Fernández,et al.  Highly variable mutational profile of ASXL1 in myelofibrosis , 2016, European journal of haematology.

[7]  S. Orkin,et al.  Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis , 2016, The Journal of experimental medicine.

[8]  A. Iwama,et al.  The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition , 2016, The Journal of experimental medicine.

[9]  R. Hutchison,et al.  Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm. , 2016, Blood.

[10]  O. Abdel-Wahab,et al.  ASXL1 plays an important role in erythropoiesis , 2016, Scientific Reports.

[11]  N. Kröger,et al.  Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation , 2016, Bone Marrow Transplantation.

[12]  P. Campbell,et al.  DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype , 2015, Haematologica.

[13]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[14]  Paola Guglielmelli,et al.  Effect of mutation order on myeloproliferative neoplasms. , 2015, The New England journal of medicine.

[15]  David A. Williams,et al.  Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity , 2015, Haematologica.

[16]  T. Golub,et al.  Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. , 2014, Blood.

[17]  Christian Beisel,et al.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. , 2014, Blood.

[18]  Lincoln D. Stein,et al.  Identification of pre-leukemic hematopoietic stem cells in acute leukemia , 2014, Nature.

[19]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[20]  N. Kröger,et al.  CD133 marks a stem cell population that drives human primary myelofibrosis , 2013, Haematologica.

[21]  M. Heuser,et al.  SETBP1 mutation analysis in 944 patients with MDS and AML , 2013, Leukemia.

[22]  E. Currie,et al.  CD34(-) cells at the apex of the human hematopoietic stem cell hierarchy have distinctive cellular and molecular signatures. , 2013, Cell stem cell.

[23]  Somasekar Seshagiri,et al.  Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation , 2012, Science.

[24]  Mithat Gonen,et al.  Recurrent Somatic TET2 Mutations in Normal Elderly Individuals With Clonal Hematopoiesis , 2012, Nature Genetics.

[25]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[26]  Iannis Aifantis,et al.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. , 2012, Cancer cell.

[27]  Y. Sasaki,et al.  Development of a high-resolution purification method for precise functional characterization of primitive human cord blood-derived CD34-negative SCID-repopulating cells. , 2011, Experimental hematology.

[28]  N. Kröger,et al.  Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT , 2010, Bone Marrow Transplantation.

[29]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[30]  D. Birnbaum,et al.  Mutations of ASXL1 gene in myeloproliferative neoplasms , 2009, Leukemia.

[31]  N. Kröger,et al.  Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. , 2007, Blood.

[32]  P. Campbell,et al.  The myeloproliferative disorders. , 2006, The New England journal of medicine.

[33]  Irving L. Weissman,et al.  Prospective isolation of human clonogenic common myeloid progenitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Dick,et al.  A newly discovered class of human hematopoietic cells with SCID-repopulating activity , 1998, Nature Medicine.

[35]  R. Johnson,et al.  Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species , 1997, Nature Medicine.